Read Time:9 Second
NeuroSense Therapeutics Ltd.’s stock rose 6.5% Tuesday, as analysts cheered data from the biotech’s late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
